Distinguishing Multiple System Atrophy from Parkinson's is Key to Patient Care

A recent expert meeting in Seoul highlighted the critical need for South Korea to officially recognize Multiple System Atrophy (MSA) as a distinct rare disease, separate from Parkinson's disease. Currently, patients diagnosed with MSA are administratively registered under Parkinson's disease, a classification that obscures accurate patient statistics and prevents the implementation of specialized care and support systems tailored to MSA's unique characteristics.

“

MSA is a degenerative brain disease that damages various neurological systems simultaneously.

During a virtual meeting connecting South Korean and Danish patient families, Anja Bernai Ringe, whose husband passed away from MSA, shared insights into Denmark's supportive policies for rare diseases. These include rapid diagnosis, specialized treatment and rehabilitation, professional caregiving support, and community-based care coordination. Ringe emphasized that such systems were invaluable to her family during their difficult journey.

“

While Parkinson's disease damages dopamine neurons in the brain, and ALS damages peripheral and motor neurons, MSA... damages various neurological systems together.

MSA is a progressive neurodegenerative disorder that affects multiple neurological systems, leading to rapid loss of motor function, typically within five years of onset, often in patients in their late 50s. Unlike Parkinson's disease, which primarily affects dopamine-producing neurons, MSA involves damage to various parts of the nervous system, including the cerebellum and autonomic nervous system. This leads to a complex set of symptoms, including those resembling Parkinson's (bradykinesia, rigidity), autonomic dysfunction (orthostatic hypotension, bladder issues), and cerebellar ataxia (balance problems).

“

The most important early symptom of MSA can be REM sleep behavior disorder, where patients scream or move violently during sleep.

Patients and their families, along with medical professionals, are urging the government to reclassify MSA. They argue that its distinct clinical features, rapid progression, and specific care needs warrant separate designation. This reclassification is seen as crucial for developing targeted therapies, improving diagnostic accuracy, and ensuring patients receive appropriate medical and social support, ultimately allowing them to navigate the "golden time" for treatment more effectively. The development of new drugs for MSA is progressing, but their successful integration into patient care hinges on proper disease recognition and classification.

“

MSA is a disease that clearly differs from Parkinson's disease, and it should now be distinguished and designated as a rare disease.